Skip to Content

Sumitomo Pharma Co Ltd - Stock Quote DNPUF

Rating as of

Morningstar's Sumitomo Pharma Co Ltd Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Sumitomo Pharma Co Ltd's Company Profile

Business Description

Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

6-8, Doshomachi 2-chome, Chuo-ku
Osaka, 541-0045, Japan
T +81 662035321
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Mar 31, 2022
Fiscal Year End Mar 31, 2022
Stock Type
Employees 6,987